Clinical trial
Trastuzumab and Capecitabine in Treating Women With Metastatic Breast Cancer
NCT00107393 · Tohoku University, Other · Completed
Key facts
| NCT number | NCT00107393 |
|---|---|
| Title | Trastuzumab and Capecitabine in Treating Women With Metastatic Breast Cancer |
| Official title | Phase II Study of Trastuzumab (Herceptin) and Capecitabine (Xeloda) in Women With Taxanes and Anthracyclines Refractory Metastatic Breast Cancer and HER2 Over-Expression |
| Lead sponsor | Tohoku University, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | trastuzumab, capecitabine |
| Enrollment | 75 |
| Start date | Jun 1, 2003 |
| Primary completion | May 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Apr 6, 2005 |
| Last update posted | Jul 10, 2013 |
| Countries | Japan |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: